Is Mochi Health Legit? What the Lawsuit, Aequita Shutdown, and BBB Records Show

Is Mochi Health a real company, or a scam?

Mochi Health is a real, operating telehealth company. It is not a site that takes your card and disappears. It is incorporated as Mochi Health Corp. and based in San Francisco. Physician Myra Ahmad founded it in 2022.

Mochi says it has served more than 500,000 patients across the United States. It also says it has more than 400 board-certified providers. Several of its doctors are also certified in obesity medicine, the specialty of weight care.

Mochi itself is a technology and admin company. The doctors and nurse practitioners work for independent medical practices tied to Mochi, and those practices provide the care. Real clinicians write the prescriptions. Partner pharmacies fill them.

That does not mean its record is clean. Two drugmakers are suing Mochi. A state regulator shut down a pharmacy that used to fill its orders. And Mochi sells compounded GLP-1s. These are pharmacy-made versions of weight-loss drugs like Wegovy and Zepbound. The FDA is narrowing the rules around them. Here is what each issue means, with links to the original records.

Has Mochi Health been sued? The Eli Lilly and Novo Nordisk lawsuits

Yes, twice. Eli Lilly, the maker of Zepbound and Mounjaro, sued first, on April 23, 2025. The suit names Mochi Health Corp., its medical practices and Aequita, its pharmacy partner at the time. It was filed in federal court in Northern California as case No. 3:25-cv-03534. The same week, Lilly sued Henry Meds, Willow Health and Fella Health over similar marketing.

Lilly's claims are about marketing, not about harm to a patient. Lilly says Mochi called its compounded tirzepatide "personalized" when it was not. It also says Mochi used Lilly's own Zepbound studies to sell its compounded version. Last, it says Mochi controlled prescribing at its affiliated practices. California law bars a company from making medical decisions for doctors.

On August 4, 2025, Novo Nordisk, the maker of Wegovy and Ozempic, filed its own suit in the same court. Novo says Mochi implied its compounded semaglutide was FDA-approved. It also says Mochi's website showed images of real Ozempic pens. The case is No. 5:25-cv-06563.

Both are civil disputes between drugmakers and a competitor. Neither is a criminal case, an FDA action or a patient lawsuit over harm. Mochi has answered in public, too. In a statement on its website, it calls Lilly's suit a reaction to competition. It says it will keep offering affordable obesity care.

Where do the lawsuits stand in late 2026?

Both cases are moving forward, and neither is resolved. In the Lilly case, the judge dismissed Lilly's first complaint in October 2025. Lilly refiled. In April 2026, Judge Jacqueline Scott Corley let its false-advertising claims go forward. She also kept its unfair-competition claims, which accuse Mochi of unlawful business practices under California law. She dismissed a broader conspiracy claim but let Lilly try again.

Lilly refiled again in May 2026. On September 8, 2026, the judge dismissed the conspiracy theory tied to false advertising. She kept a narrower one claiming Aequita joined an unfair-competition scheme. Mochi filed its answer in September 2026. A jury trial is set for January 2028.

In the Novo case, the judge denied Mochi's request to dismiss on July 1, 2026. Mochi filed its answer in July. The two sides are now exchanging evidence. The court has also referred the case to private settlement talks.

No court has found that Mochi committed fraud. There has been no settlement or verdict in either case. The Lilly docket, the court's public list of filings, shows the latest steps.

Is Mochi Health safe? What happened with the Aequita pharmacy shutdown

This is the most serious safety event in Mochi's history. Aequita Pharmacy, in Kirkland, Washington, was one of Mochi's main suppliers. On March 13, 2025, Washington's pharmacy board ordered it to stop compounding. The state's notice cites untrained staff doing sterile compounding. That is the making of injectable medicine in germ-free conditions. The state also issued a Notice of Immediate Jeopardy. It said Aequita's practices put people at risk of serious injury or death.

A June 2026 KING 5 and NBC Bay Area investigation added detail from former employees. They said unlicensed temporary workers were picked up in home-improvement store parking lots. They described cheap vials that shattered. They said frozen popsicles were used when ice packs ran out. Inspectors also found prescriptions ready to mail that had expired, some nearly nine months earlier.

The link to Mochi is close. Lilly's lawsuit says Mochi's CEO, Myra Ahmad, and her husband control the companies it sued, Aequita included. At one point, Aequita shipped about 20,000 prescriptions a week for Mochi.

Aequita closed in April 2025. Mochi patients faced shipping delays while orders moved to other pharmacies.

Mochi now spreads its orders across a network of partner pharmacies. It runs them as a marketplace, so you and your provider can see the options and choose one. That is a sensible fix, but it does not undo what happened.

So ask which pharmacy will fill your prescription. Then check that its state license is current and has no restrictions.

Has the FDA taken action against Mochi Health?

The FDA has not sent Mochi Health a warning letter, as of October 17, 2026. A warning letter is the FDA's formal notice that a company broke its rules. Mochi was not among the 30 telehealth companies the FDA warned on March 3, 2026. Those letters targeted ads implying compounded GLP-1s match approved drugs.

Having no letter is not a safety check, though. Mochi's compounded semaglutide and tirzepatide are still not FDA-approved. Its brand-name drugs, such as Wegovy and Zepbound, are.

The bigger change is to the rules themselves. On April 30, 2026, the FDA made a proposal about these drugs. It would keep semaglutide, tirzepatide and liraglutide off its list of bulk ingredients that 503B facilities may use. A 503B outsourcing facility makes large batches and registers with the FDA. A 503A pharmacy fills one patient's prescription at a time.

The proposal covers 503B facilities only, not 503A pharmacies. Mochi's partner pharmacies can be either kind, so ask which one fills your order. Public comments closed on July 30, 2026. The FDA had not made a final decision as of October 17, 2026.

What are Mochi Health's BBB and Trustpilot ratings?

Both are now positive, with one big caveat. The Better Business Bureau, or BBB, gives Mochi an A rating as of October 17, 2026. Mochi has been BBB-accredited since August 24, 2026. That means it signed on to the BBB's standards for treating customers. The profile also lists 1,422 complaints.

BBB says those complaints are about cancellations. It adds a warning of its own. Mochi's membership and its medicine subscriptions are separate, and you must cancel each one. Older summaries that quote a B-, an F or no accreditation are out of date.

On Trustpilot, Mochi scores 4.5 out of 5 across about 19,500 reviews, as of October 2026. Trustpilot's summary of recent reviews says people praise the providers and how easy visits are to book. Unhappy reviewers mention missed appointments, refill trouble and medicine that arrived warm.

What are people actually complaining about?

The main complaint is the two-part billing. The membership and the medicine are separate subscriptions. Some patients cancel one, assume both have stopped, and get charged again the next month.

Refunds are limited too. Mochi's refund policy says all prescription sales are final. Shipping delays from the Aequita period show up often in older complaints.

Reddit posts are personal stories, not records. Mochi also runs its own official subreddit, so keep that in mind as you read. Weigh detailed, dated posts more than a one-line warning. A cancellation dispute is frustrating, but it is a different problem from a safety or fraud claim.

Red flags to check yourself before you pay

• Ask which pharmacy fills your prescription. Then confirm its state license is current and has no restrictions. It is the most concrete check you can make.
• Cancel both parts when you stop. The membership and the medicine are separate subscriptions. Cancelling one does not cancel the other.
• Know that medicine is final sale. Mochi does not refund prescription medicine once it is sold.
• Read more than one review site. BBB's A rating with 1,422 complaints and Trustpilot's 4.5 describe the same company.
• Know what the lawsuits are. They are marketing and unfair-competition disputes brought by drugmakers. They are not fraud findings, FDA actions or proof the medicine is unsafe.
• Expect the price to rise with your dose. Compounded semaglutide starts at about $140 a month, membership included. Tirzepatide starts at about $170. New members get the first month of membership free, though not in every state. The Mochi cost breakdown shows every dose.

The bottom line: is Mochi Health legit?

Yes. Mochi Health is a real company with real doctors and real patients. State-licensed pharmacies fill its prescriptions. It is also now BBB-accredited.

It is still being sued by two drugmakers over its marketing. It also sells compounded GLP-1s while the FDA narrows the rules. None of that adds up to fraud.

The Aequita shutdown is the fair knock. It showed what goes wrong when one pharmacy handles too much with too little oversight. That is why asking which pharmacy fills your prescription is worth two minutes.